Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.

Tejas Patil,Rao Mushtaq,Sydney Marsh,Christine Azelby,Miheer Pujara,Dara L. Aisner,William T. Purcell,Erin L. Schenk,Paul A. Bunn,Jose Maria Pacheco,D. Ross Camidge,Robert C. Doebele

Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.

2019

Tejas Patil
Rao Mushtaq
Sydney Marsh
Christine Azelby
Miheer Pujara
Dara L. Aisner
William T. Purcell
Erin L. Schenk
Paul A. Bunn
Jose Maria Pacheco
D. Ross Camidge
Robert C. Doebele

9090Background: The clinicopathologic characteristics and optimal treatment strategies for non-sensitizing EGFR (ns-EGFR) and HER2 activating mutations in NSCLC remain unclear. Methods: Single-cent...

Keywords:

Oncology
Single Center
Pathology
Retrospective cohort study
Internal medicine
Medicine
her2 erbb2
optimal treatment
treatment outcome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations